News
UCLA TDG Innovation Magazine Winter 2024
Welcome to the Winter 2024 Edition of UCLA TDG's Innovation Magazine.
This is our year-end wrap up with annual performance metrics and global rankings.
In this edition you will find stories on:
-Cytovale $100M Funding
-UCLA Innovation Fund supporting early stage research
-Lyell Immunopharma acquires ImmPACT Bio
-Pictor Labs $30M Funding
Q&A with Arvin Patel: How IP Can Help Your Company Win & What It Means for AI Founders
Q&A with Arvin Patel: How IP Can Help Your Company Win & What It Means for AI Founders
Precision Surgery Technologies and Concrete.ai win Draper Innovation Showcase 2024
Photo of Maie St John of Percision Surgery Technologies accepting the First Place award
Los Angeles, CA October 24, 2024 --- Precision Surgery Technologies wins First Place and Concrete.ai wins Third Place at the Draper Innovation Showcase!
Lyell Immunopharma to Acquire ImmPACT Bio
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Cytovale Completes $100 Million Series D Funding
SAN FRANCISCO, Oct.
Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss
Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1 NEWS PROVIDED BY Pelage Pharmaceuticals
Aug 13, 2024, 08:00 ET
Inclusive trial recruiting women and men with androgenetic alopecia to evaluate safety and preliminary efficacy of PP405, a topical treatment designed to reactivate dormant hair follicle stem cells
Trethera Receives $2M NIH Grant
Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million NIH Small Business Innovation Research (SBIR) grant for preclinical studies treating acute disseminated encephalomyelitis (ADEM), a neurologic disease principally of children. Trethera’s clinical stage and first-in-class drug, TRE-515, holds the only FDA Orphan Drug designation for ADEM.